Effect of Conlaite Injection Combined with Sindilizumab and Bevacizumab in the Treatment of Patients with Liver Cancer and Its Influence on Liver Function and Quality of Life
Objective:To explore the efficacy of Kanglaite injection combined with Sindilizumab and bevacizumab in the treatment of liver cancer patients and the influence on liver function and quality of life.Methods:A total of 90 patients with liver cancer who were hospitalized from 2021.2 to 2024.2 were selected and divided into control group(sintilimab+bevacizumab treatment)and observation group(Conlett injection combined sintilimab+bevacizumab treatment),45 cases in each group.Compare the two groups of relevant indicators.Results:The total effective rate of observation group was higher than that of control group(P＜0.05).After treatment,the levels of TBil,DBil,AST and AST in the observation group were lower than those in the control group(P＜0.05).After treatment,two groups of CD4+and NK index levels,CD8+index levels,there are differences between the observation group than the control group comparison(P＜0.05).After treatment,the levels of CEA,AFP and CA1 99 in observation group were lower than those in control group(P＜0.05).After treatment,the KPS score of observation group was higher than that of control group(P＜0.05).Conclusion:Kanglaite injection combined with sindillizumab and bevacizumab in the treatment of liver cancer patients can increase the total response rate,improve liver function,enhance immune function,reduce the level of tumor markers,and improve the quality of life.
Kanglaite injectionSindilimabBevacizumabLiver cancerLiver function
万方数据
维普
